Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IVAX Insider Trading -- Ignore unavailable to you. Want to Upgrade?

To: 5,17,37,5,101,... who wrote (288)	12/17/1997 8:23:00 AM
From: flickerful	Read Replies (1) \| Respond to of 756

Wednesday December 17, 7:58 am Eastern Time Company Press Release SOURCE: IVAX Corporation IVAX Announces Generic Drug Approval for Verapamil; FDA Approval Completes IVAX's Verapamil Line MIAMI, Dec. 17 /PRNewswire/ -- IVAX Corporation (Amex: IVX - news) today announced that the United States Food and Drug Administration approved an Abbreviated New Drug Application for the generic pharmaceutical product verapamil HCl ER in 120 mg tablets. Verapamil is indicated for the management of hypertension, and is the generic equivalent of Knoll Pharmaceutical Company's Isoptin(R) SR and G.D. Searle & Co.'s Calan(R) SR. The product will be marketed by IVAX's wholly owned subsidiary, Zenith Goldline Pharmaceuticals, Inc. and sales have commenced. Zenith Goldline now has authority to manufacture and market all three dosage strengths of verapamil extended release tablets. IVAX Corporation, headquartered in Miami, Florida, is a holding company with core subsidiaries engaged primarily in the research, development, manufacture and marketing of generic and branded pharmaceuticals. SOURCE: IVAX Corporation ------------------------------------------------------------------------